Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer Transcript
Le azioni di Compass Therapeutics affrontano volatilità dopo risultati misti dello studio, dice William Blair